Starting news article english 20 March 2013

Clifford Chance advises Amdipharm Mercury Company Limited (AMCo) on its acquisition of the Fucithalmic® pharmaceutical product business of LEO Pharma A/S

International law firm Clifford Chance advised Amdipharm Mercury Company Limited (AMCo) on its acquisition of the global Fucithalmic® pharmaceutical product business from Danish pharmaceutical company LEO Pharma A/S for an undisclosed sum. The transaction is expected to close in April 2013.

Fucithalmic is a human use ophthalmic gel for the topical treatment of bacterial conjunctivitis. It has annual sales of €30 million and is sold in over 90 countries world-wide.

AMCo is an international specialty pharmaceuticals group.  It was formed recently from a merger of the  Amdipharm and Mercury Pharma businesses. It specialises in off-patent niche pharmaceuticals and has pro forma revenues of around £250 million generated in 112 countries. Clifford Chance acted for Cinven on its 2012 acquisition of both the Amdipharm and Mercury Pharma businesses and has been closely involved in the merger, which was announced earlier this month.

The Clifford Chance team was led by London Corporate Partner Andre Duminy and associate Ed Freeman, as well as Cinven client relationship Partner Jonny Myers. The team included Anna Blest and Nick Lee-Morrison (IP, corporate and commercial arrangements), Martin Forbes (financing advice), Helen Johnson and Simon Corzberg (tax issues) and Greg Olsen and Christopher Duff (competition aspects). Bruun Hjejle advised on Danish law aspects.